 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
 |
Veterinarian News
Examining the Efficacy of Toceranib Phosphate (Palladia) as a Primary and/or Adjuvant Agent in the Treatment of Feline Oral Squamous Cell Carcinoma |
12/28/2011
This is a non-randomized study to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma. 
Examining the Efficacy of Toceranib Phosphate (Palladia) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma |
12/28/2011
Non-randomized study examining the efficacy of toceranib alone or radiation therapy plus toceranib. The financial incentive includes toceranib and follow-up rechecks depending on the study arm the patient is in.
Partially funded clinical trial for dogs with solid tumors |
08/08/2011
Trial Summary A total of 15 dogs with spontaneous tumors are expected to be enrolled into this clinical trial. Dogs will receive a single dose of the Test Article over 1 hr, for two consecutive days. Dogs will need to remain in the hospital for the first 48 hours of the study for blood samples and toxicity evaluation. Dogs will be evaluated on Day 8 of the study at which time the study will end.
Funded Clinical Trial for Dogs with melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma. |
08/08/2011
Trial Summary A minimum of 100 dogs with solid tumors will be treated with modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required at 2,4,7, and 14 days. While the patient remains on study, there will also be rechecks at 1 and 2 months from the initial treatment.
Clinical Trial for Dogs with Osteosarcoma |
03/29/2011
NEVOG is currently participating in a clinical trial for canine osteosarcoma. Dogs enrolled in this study will receive carboplatin chemotherapy and then will be randomized to receive either Palladia/piroxicam/cyclophosphamide or piroxicam/cyclophosphamide alone. Patients must return every 3 weeks during the chemotherapy phase of the trial. Once the second phase of the trial is started, patients must return at Days 14 and 28 then every 28 days thereafter. This study is partially funded. Patients enrolled on the study will receive free carboplatin, free Palladia if randomized to receive this drug and a financial incentive for the rechecks.
What You Need to Know About Palladia (toceranib phosphate) |
06/22/2009
Pfizer recently received FDA approval for a novel drug, Palladia that is indicated for the treatment of mast cell tumors in dogs.
Emergency on call for active patients |
08/21/2008
NEVOG is pleased to offer an on-call after hours emergency service. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
|
 |
info@nevog.com
781 684 8777
781 684 8688
180 Bear Hill Rd.
Suite C Waltham, MA 02451
Get Directions
11 Bourne Bridge Approach
Buzzards Bay, MA 02532
Get Directions
336 Abby Rd.
Manchester, NH 03103
Get Directions
15 Piscataqua Dr.
Portsmouth, NH 03801
Get Directions